NEW YORK (PRWEB)
February 13, 2023
Novita Pharmaceuticals, Inc. (“Novita” or the “Company”), a privately held clinical-stage pharmaceutical company dedicated to developing novel cancer drugs based on its proprietary fascin inhibitor technology, today announced that the Company’s Board of Directors has appointed Alan Wills as its Chief Executive Officer.
Mr. Wills joined Novita as Chief Executive Officer on February 6, 2023, bringing extensive experience in the global biopharmaceutical industry, notably in business development, corporate strategy, M&A and licensing, and alliance management. Prior to joining Novita. Mr. Wills was Executive Vice President, Strategy & Business Development, at CSL Group. He previously served in a range of progressively senior level roles in Corporate Strategy, Business Development, Global Marketing and Portfolio Management at Pfizer, Bristol-Myers Squibb, and Auxilium Pharmaceuticals. In his earlier career, he worked at the Boston Consulting Group, Lucile Packard Children’s Hospital at Stanford, and United Healthcare. He holds a Master of Business Administration from Harvard Business School.
“Alan is a seasoned pharmaceutical senior executive and a strong strategic thinker and executer,” said Dr. Xin-Yun Huang, Chairman of the Board and a co-founder of Novita. “He brings a depth of business experience and acumen that will be a perfect complement to Novita’s founding team.”
“We are delighted to have recruited a talent like Alan,” said Dr. Jillian Zhang, President and Chief Scientific Officer, and a co-founder of Novita. “Our Company’s first-in-class fascin inhibitor NP-G2-044 is in the midst of a phase 2 clinical study. It is great timing for Alan to join us at this stage as we continue to advance the development of NP-G2-044 as a breakthrough cancer therapy.”
“It’s an exciting time to join Novita, with the Company’s lead compound moving through its phase 2 program and generating solid early data,” said Mr. Wills. “I look forward to helping Novita advance the development of new and innovative cancer therapies that will address critical unmet medical needs.”
About Novita Pharmaceuticals, Inc.
Novita Pharmaceuticals, Inc. (“Novita” or the “Company”) is a privately held clinical-stage biopharmaceutical company dedicated to developing ground-breaking drugs based on its proprietary fascin inhibitor technology to prevent and treat cancer metastasis and at the same time to boost anti-cancer immune responses. Cancer metastasis is the primary cause of over 90% of deaths of cancer patients and yet there is no drug specifically and directly targeting metastasis on the market today. In addition, while Immuno-Oncology (IO) with anti-PD-1 immune checkpoint inhibitors has made a significant impact on the treatment of many types of cancer, most cancer patients do not respond to current IO treatments. Novita aims to address both these important medical needs by developing inhibitors of fascin, a key protein critically involved in tumor cell motility and highly expressed in tumor cells and in antigen-presenting cells in the tumor tissues. The Company’s lead asset, a small-molecule fascin inhibitor NP-G2-044 has been shown in preclinical studies to block tumor cell migration, invasion, and metastasis. In animal models, NP-G2-044 in combination with immune checkpoint inhibitors demonstrated synergistic efficacy that tripled overall survival rates in comparison to IO alone. The multicenter Phase 2 clinical trial of NP-G2-044 titled “NP-G2-044 as Monotherapy and Combination Therapy in Patients with Advanced or Metastatic Solid Tumor Malignancies” is currently ongoing and open for patient enrollment.
For more clinical trial information, please go to:
https://clinicaltrials.gov/ct2/show/NCT05023486
Cautionary Note Regarding Forward-Looking Statements
This press release contains certain forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in the forward-looking statements. These statements are based on a number of assumptions and estimates that are inherently subject to significant uncertainties and contingencies, many of which are beyond the Company’s control, and reflect future business decisions, which are subject to change. Among those factors that could cause actual results to differ materially from those described in the forward-looking statements are the risks associated with the Company’s being a development stage company with uncertain revenue streams; uncertain results or outcomes during clinical trials; certain rights owned by others over the Company’s intellectual property; failure to raise necessary capital in the future; the loss of key personnel; competition from other larger, better-capitalized peers; the Company’s reliance on incorrect assumptions regarding the market for its products, the costs of developing, manufacturing and marketing the Company’s products, and the timing and receipt of regulatory approval for the Company’s products; adverse economic conditions; and other risks. In light of the significant uncertainties inherent in the forward-looking statements, the inclusion of any such statement should not be regarded as a representation by Novita or any other person that the Company’s objectives or plans will be achieved.
Contact Info:
Christy Shue
cshue@novita-pharm.com
Share article on social media or email: